GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2025, and provided business updates. Cash Position and Outlook As of December 31, 2025, GenSight Biologics' cash and cash equ